MJA
MJA

Patients expect transparency in doctors’ relationships with the pharmaceutical industry

Med J Aust 2009; 190 (2): 65-68.
  • Martin H N Tattersall1,2
  • Aneta Dimoska2
  • Kevin Gan1

  • 1 Central Clinical School, Faculty of Medicine, University of Sydney, Sydney, NSW.
  • 2 Medical Psychology Research Unit, University of Sydney, Sydney, NSW.

Correspondence: mtatt@med.usyd.edu.au

Acknowledgements: 

We are grateful to the staff of the Mullumbimby Medical Centre, Dr Melanie Griffith and staff at the Health@GreenSquare Clinic in Zetland, Dr Renata Chapman-Konarska at the Victoria Avenue Medical Centre in Chatswood, and A/Prof Ian Marshall, Dr Sue Britton and staff at the University of Sydney Health Service for their support of this project, and the patients who completed the survey. We acknowledge the helpful comments of Ian Kerridge and Itay Keshet on a draft of the manuscript, and the Department of Cancer Medicine Research Fund, University of Sydney, for providing the funds to complete this study.

Competing interests:

None identified.

  • 1. Campbell EG, Gruen RL, Mountford J, et al. A national survey of physician–industry relationships. N Engl J Med 2007; 356: 1742-1750.
  • 2. Mansfield P, Lexchin J. Case study 5 report: new drugs. Sydney: National Prescribing Service, Dec 1999. http://www.nps.org.au/__data/assets/pdf_file/0019/35452/Case_5_results.pdf (accessed Nov 2008).
  • 3. Henry DA, Kerridge IH, Hill SR, et al. Medical specialists and pharmaceutical industry-sponsored research: a survey of the Australian experience. Med J Aust 2005; 182: 557-560. <MJA full text>
  • 4. Halperin EC, Hutchison P, Barrier RC Jr. A population-based study of the prevalence and influence of gifts to radiation oncologists from pharmaceutical companies and medical equipment manufacturers. Int J Radiat Oncol Biol Phys 2004; 59: 1477-1483.
  • 5. Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There’s no such thing as a free lunch. Chest 1992; 102: 270-273.
  • 6. Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med 1982; 73: 4-8.
  • 7. Peay MV, Peay ER. The role of commercial sources in the adoption of a new drug. Soc Sci Med 1988; 26: 1183-1189.
  • 8. Chren MM, Landefeld CS. Physicians’ behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA 1994; 271: 684-689.
  • 9. Scott IA. On the need for probity when physicians interact with industry. Intern Med J 2006; 36: 265-269.
  • 10. Tattersall MHN, Kerridge IH. Doctors behaving badly [letter]? Med J Aust 2006; 185: 674-675. <MJA full text>
  • 11. Studdert DM, Mello MM, Brennan TA. Financial conflicts of interest in physicians’ relationships with the pharmaceutical industry — self-regulation in the shadow of federal prosecution. N Engl J Med 2004; 351: 1891-1900.
  • 12. Australian Medical Association. AMA position statement: doctors’ relationships with the pharmaceutical industry — 1994. Revised 2002. http://www.ama.com.au/web.nsf/doc/WEEN-5GJ7MH (accessed Dec 2007).
  • 13. Weinfurt KP, Friedman JY, Allsbrook JS, et al. Views of potential research participants on financial conflicts of interest: barriers and opportunities for effective disclosure. J Gen Intern Med 2006; 21: 901-906.
  • 14. Levinson W, Kao A, Kuby AM, Thisted RA. The effect of physician disclosure of financial incentives on trust. Arch Intern Med 2005; 165: 625-630.
  • 15. Hampson LA, Agrawal M, Joffe S, et al. Patients’ views on financial conflicts of interest in cancer research trials. N Engl J Med 2006; 355: 2330-2337.
  • 16. Moynihan R. Doctor treats to be disclosed. The Australian 2006; 26 Jul.
  • 17. Mechanic D. In my chosen doctor I trust [editorial]. BMJ 2004; 329: 1418-1419.
  • 18. Pearson SD, Kleinman K, Rusinak D, Levinson W. A trial of disclosing physicians’ financial incentives to patients. Arch Intern Med 2006; 166: 623-628.
  • 19. Pearson SD, Hyams T. Talking about money: how primary care physicians respond to a patient’s question about financial incentives. J Gen Intern Med 2002; 17: 75-78.
  • 20. Federal Court of Australia. Application by Medicines Australia Inc [2007] ACompT 4. Australian Competition Tribunal Decision, 27 June 2007.
  • 21. Cain DM, Loewenstein G, Moore DA. The dirt on coming clean: perverse effects of disclosing conflicts of interest. J Legal Stud 2005; 34: 1-25.
  • 22. Campbell EG. Doctors and drug companies — scrutinizing influential relationships. N Engl J Med 2007; 357: 1796-1797.
  • 23. Rutledge P, Crookes D, McKinstry B, Maxwell SR. Do doctors rely on pharmaceutical industry funding to attend conferences and do they perceive that this creates a bias in their drug selection? Results from a questionnaire survey. Pharmacoepidemiol Drug Saf 2003; 12: 663-667.
  • 24. Grayson A. Should docs disclose drug company ties? ABC News 2008; 4 Dec. http://abcnews.go.com/print?id=6385382 (accessed Dec 2008).

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article